Literature DB >> 20660377

Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.

Shunsuke Yagi1, Etsuji Yoshikawa, Masami Futatsubashi, Masamichi Yokokura, Yujiro Yoshihara, Tatsuo Torizuka, Yasuomi Ouchi.   

Abstract

UNLABELLED: It is still unclear why some early Parkinson disease (PD) patients with unilateral parkinsonism develop bilateral parkinsonism soon after the diagnosis is made as Hoehn and Yahr (HY) stage 1 and others remain stable for a long time. Here, we examined in vivo changes in the brain dopaminergic system using PET with a dopamine transporter radiotracer, (11)C-2-B-carbomethoxy-3B-(4-fluorophenyl) tropane ((11)C-CFT), to elucidate the pathophysiologic characteristics of the dopamine system in early converters.
METHODS: Twelve drug-naïve PD patients with HY stage 1 disease and 8 age-matched healthy subjects participated in this study. Clinical evaluation of their parkinsonism was performed monthly until their HY stage 1 (unilateral parkinsonism) disease had become stage 2 (bilateral parkinsonism) disease according to the Unified Parkinson Disease Rating Scale. The endpoint of the follow-up study was the time of the conversion. Region-of-interest analysis was used to examine (11)C-CFT binding in the mesocortical (nucleus accumbens, caudate, orbitofrontal cortex) and nigrostriatal (putamen) dopamine projection regions. Multiregression analyses between these PET data and clinical parameters were performed within the PD group.
RESULTS: Between-group comparisons showed that, irrespective of the duration of conversion, all PD patients clinically diagnosed at HY stage 1 had a significant reduction in (11)C-CFT binding in the bilateral striatum (affected, -46%; unaffected, -35%). Regression analysis showed that the level of (11)C-CFT binding in the nucleus accumbens and orbitofrontal cortex on the unaffected side was significantly positively correlated with the conversion interval. This positive correlation indicates that the more severe a dysfunction presents in the mesocortical dopamine system on the seemingly intact side, the more rapidly the parkinsonism proceeds to the intact side (bilateral parkinsonism).
CONCLUSION: The finding of bilateral reduction in the striatal (11)C-CFT binding even in HY stage 1 PD patients confirms that molecular changes in the dopamine system precede clinical phenotype, suggesting an advantage of PET for detecting an early abnormality of the disease. The spread of parkinsonism to the unaffected side soon after the diagnosis of HY stage 1 PD may be related to the degree of mesocortical dopamine dysfunction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660377     DOI: 10.2967/jnumed.110.076802

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review.

Authors:  Wei-Xi Xiong; Yi-Min Sun; Rong-Yuan Guan; Su-Shan Luo; Chen Chen; Yu An; Jian Wang; Jian-Jun Wu
Journal:  J Neurol       Date:  2016-07-08       Impact factor: 4.849

2.  In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.

Authors:  Yumi Oboshi; Yasuomi Ouchi; Shunsuke Yagi; Satoshi Kono; Noriyoshi Nakai; Etsuji Yoshikawa; Masami Futatsubashi; Tatsuhiro Terada; Kang Kim; Kiyoshi Harada
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-11       Impact factor: 6.200

3.  Effect of subthalamic nucleus stimulation during exercise on the mesolimbocortical dopaminergic region in Parkinson's disease: a positron emission tomography study.

Authors:  Takao Nozaki; Kenji Sugiyama; Shunsuke Yagi; Etsuji Yoshikawa; Toshihiko Kanno; Tetsuya Asakawa; Tae Ito; Tatsuhiro Terada; Hiroki Namba; Yasuomi Ouchi
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

4.  Pharmacokinetic Modeling of 18F-FDOPA PET in the Human Brain for Early Parkinson's Disease

Authors:  Wirunpatch Buratachwatanasiri; Maythinee Chantadisai; Jaruwan Onwanna; Yuda Chongpison; Yothin Rakvongthai; Kitiwat Khamwan
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

5.  Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease.

Authors:  Valtteri Kaasinen
Journal:  Ann Clin Transl Neurol       Date:  2015-12-05       Impact factor: 4.511

Review 6.  Parkinson's disease dementia: a neural networks perspective.

Authors:  James Gratwicke; Marjan Jahanshahi; Thomas Foltynie
Journal:  Brain       Date:  2015-04-16       Impact factor: 13.501

Review 7.  The BSSG rat model of Parkinson's disease: progressing towards a valid, predictive model of disease.

Authors:  Jackalina M Van Kampen; Harold A Robertson
Journal:  EPMA J       Date:  2017-09-04       Impact factor: 6.543

8.  Discriminative pattern of reduced cerebral blood flow in Parkinson's disease and Parkinsonism-Plus syndrome: an ASL-MRI study.

Authors:  Lina Cheng; Xiaoyan Wu; Ruomi Guo; Yuzhou Wang; Wensheng Wang; Peng He; Hanbo Lin; Jun Shen
Journal:  BMC Med Imaging       Date:  2020-07-13       Impact factor: 1.930

9.  Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent.

Authors:  Donglang Jiang; Xiuhong Lu; Zijing Li; Nicklas Rydberg; Chuantao Zuo; Fangyu Peng; Fengchun Hua; Yihui Guan; Fang Xie
Journal:  Front Neurosci       Date:  2019-01-15       Impact factor: 4.677

10.  A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson's Disease for the Study of Non-Motor Symptoms.

Authors:  Débora Masini; Carina Plewnia; Maëlle Bertho; Nicolas Scalbert; Vittorio Caggiano; Gilberto Fisone
Journal:  Biomedicines       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.